Financière de Tubize SA Rendimento dei dividendi
Cos'è Rendimento dei dividendi di Financière de Tubize SA?
Rendimento dei dividendi di Financière de Tubize SA è 0.89%
Qual è la definizione di Rendimento dei dividendi?
Il rendimento dei dividendi rappresenta il rapporto tra i dividendi distribuiti agli azionisti per azione e il prezzo di mercato per azione nel corso di un anno finale.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Rendimento dei dividendi di aziende nel Health Care settore su EURONEXT rispetto a Financière de Tubize SA
Cosa fa Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Aziende con rendimento dei dividendi simili a Financière de Tubize SA
- Knight-Swift Transportation Inc ha Rendimento dei dividendi di 0.88%
- Colgate-Palmolive (India) ha Rendimento dei dividendi di 0.88%
- Pinnacle Investment Management ha Rendimento dei dividendi di 0.88%
- Symrise AG ha Rendimento dei dividendi di 0.88%
- Pinnacle Partners ha Rendimento dei dividendi di 0.88%
- Datamatics Global Services ha Rendimento dei dividendi di 0.88%
- Financière de Tubize SA ha Rendimento dei dividendi di 0.89%
- Globe Life Inc ha Rendimento dei dividendi di 0.89%
- Indo National ha Rendimento dei dividendi di 0.89%
- AFC Ajax NV ha Rendimento dei dividendi di 0.89%
- New York Times Co ha Rendimento dei dividendi di 0.89%
- Enersys ha Rendimento dei dividendi di 0.89%
- AVT Natural Products ha Rendimento dei dividendi di 0.89%